Fruit and vegetable intake reduces glaucoma risk

Article

Increased fruit and vegetable consumption reduces the risk of glaucoma, according to a study reported in the June 2008 issue of the American Journal of Ophthalmology.

Increased fruit and vegetable consumption reduces the risk of glaucoma, according to a study reported in the June 2008 issue of the American Journal of Ophthalmology.

A team, led by Anne Coleman of the Department of Ophthalmology and Jules Stein Eye Institute, UCLA, California, US, explored the association between fruit and vegetable consumption and the presence of glaucoma in a sample of 1155 women in multiple centres in the US. Of the 1155 women, 95 (8.2%) were diagnosed with glaucoma.

The investigators found that consumption of at least one serving per month of green collards and kale decreased the risk of glaucoma by 69% in women, while glaucoma risk was reduced by 64% in those who consumed more than two servings per week of carrots, compared with those who consumed fewer than one serving per week. Consumption of canned and dried peaches was also found to influence glaucoma risk, reducing risk by 47% in women who consumed at least one serving per week, in comparison to those who consumed fewer than one serving per month.

At the study's conclusion, the investigators felt that a higher consumption of fruit and vegetables reduced the risk of glaucoma; however, they conceded that further studies would need to be performed in order to establish a definitive link.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.